Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6412MR)

This product GTTS-WQ6412MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ6412MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10094MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LA480
GTTS-WQ9357MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ481MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ11387MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ10696MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA M-1095
GTTS-WQ4953MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ5920MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CK-301
GTTS-WQ12151MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MORAb-004
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW